Bronchospasm medical therapy

Jump to: navigation, search

Bronchospasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bronchospasm from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bronchospasm medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bronchospasm medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bronchospasm medical therapy

CDC on Bronchospasm medical therapy

Bronchospasm medical therapy in the news

Blogs on Bronchospasm medical therapy

Directions to Hospitals Treating Bronchospasm

Risk calculators and risk factors for Bronchospasm medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Beta 2 Agonists

Beta 2 adrenergic agonists are recommended for bronchospasm.

Muscarinic Acetylcholine Receptor Antagonist

Since the neurotransmitter, acetylcholine, is known to decrease sympathetic response by slowing the heart rate and constricting the smooth muscle tissue; ongoing research and successful clinical trials have shown that agents such as diphenhydramine, atropine and Ipratropium bromide are known to be effective for treating asthma and COPD-related symptoms.

References



Linked-in.jpg